Niclas Stiernholm Ph.D.
Niclas Stiernholm has decades of executive experience in the biotechnology industry, most recently as President and CEO of Trillium Therapeutics. Under his leadership Trillium transitioned from a discovery-based academic spin-out to a clinical-stage immuno-oncology company, listed on Nasdaq and the Toronto Stock Exchange. He joined Trillium from YM BioSciences where he was Executive Vice President and Chief Scientific Officer when the company successfully completed its Initial Public Offering in 2002. He has served on numerous corporate, scientific and non-profit boards. He received his Ph.D. in immunology from the University of Toronto.
Gunilla Ekström, M.D., Ph.D.
Gunilla Ekström is a cofounder of Gesynta Pharma and serves as a member of several boards of private and public life science companies. Having worked some 30 years in the pharma industry, including companies such as Astra Zeneca, Orexo and Karolinska Development, she has extensive experience of managing advanced pre-clinical and clinical pharmaceutical development projects and organizations.
Patrik Strömberg, Ph.D., MBA
Currently CEO of AnaCardio AB, Patrik Strömberg has close to 20 years of experience from the pharmaceutical industry and has worked in leading roles in both R&D, innovation management and business development in companies such as AstraZeneca and, most recently, as Vice President, External Innovation, Sourcing & Evaluation at Swedish Orphan Biovitrum (Sobi). He has a PhD in Biochemistry from Karolinska Institutet and earned an MBA from Stockholm University (Stockholm Business School).
Sara Mangsbo, Ph.D., Chief Scientific Officer
Sara Mangsbo, one of the founders of Strike Pharma, has over 15 years of experience in the field of immunotherapy both in the pre-clinical and clinical space. She is Associate Professor and senior lecturer in the Department of Pharmaceutical Biosciences at Uppsala University where she heads a team focused on immuno- oncology studies, specifically to improve immunotherapeutic treatments for solid tumors by developing novel immunotherapeutics and investigating their performance in new model systems.
Magnus Persson, MD, PhD, Associate Professor
Magnus is a Physician and Scientist, who early in his career successfully started a medical technology company (Aerocrine), led clinical trials at Sanofi and subsequently was a Partner in two life science Venture Capital firms, HealthCap in Stockholm and The Column Group in San Francisco. He has had a role in dozens of investments and exits. Lately he has been an independent Chairman/Board member in several private and public companies in the Nordics, as well as in the US, and worked on a weekly basis as a clinician. Magnus has been actively involved in a number of successful pharma spin-outs. He has experience from the academic incubator space as CEO at Karolinska Institutet Holding. Magnus is a Founder and Chairman of Eir Ventures Partners AB.
Dr Maarten de Château
Dr Maarten de Château is currently CEO of Sixera Pharma and Buzzard Pharmaceuticals. He serves as chairman of the Board of Atrogi, and on the Boards of Cavis Technologies and Gesynta Pharma. Maarten was Co-founder and CEO of Cormorant Pharmaceuticals – a company that developed a therapeutic antibody approach in immuno-oncology that was acquired by Bristol-Myers Squibb in 2016. Prior to that, Maarten held the position of Medical Director at Swedish Orphan Biovitrum; he has also worked in clinical development at Sanofi and as an investment bank financial analyst for five years. Maarten holds a PhD and an MD from the University of Lund, Sweden.